Skip to main content
. Author manuscript; available in PMC: 2010 Oct 23.
Published in final edited form as: Vaccine. 2009 Oct 23;27(45):6358–6362. doi: 10.1016/j.vaccine.2009.06.090

Table 1.

Fold increase in antibody amount (Amax) or antibody avidity (Ka) after vaccination

Study Virus in
vaccine and
assay		 Type of
vaccine		 Dose of H3
(µg)		 Antibody fold increase
Amax Ka(app)
BCM Five year
study, yr 1 [8]		 Philippines/82 Whole
virus		 15 2.4 ± 1.1 6.2 ± 9.8
BCM Elderly [9] Panama/99 subunit 15 1.4 ± 0.8 1.4 ± 0.6
BCM Elderly [9] Panama/99 subunit 30 1.4 ± 0.4 1.9 ± 1.4
BCM Elderly [9] Panama/99 subunit 60 1.8 ± 1.5 1.7 ± 0.9
OMRF yr1 controls California/04 subunit 15 1.6 ± 0.5 1.6 ± 1.0
OMRF yr1 cases California/04 subunit 15 1.4 ± 0.4 1.2 ± 0.4
OMRF yr2 controls Wisconsin/05 subunit 15 1.2 ± 0.2 1.4 ± 0.5
OMRF yr2 cases Wisconsin/05 subunit 15 1.2 ± 0.2 1.1 ± 0.4